Preliminary HTA fail for BMS/AZ's Forxiga in Germany
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb and AstraZeneca are the latest companies to fail Germany's AMNOG health technology appraisal data requirements. They have not supplied enough evidence to show that their Forxiga (dapagliflozin) offers any benefit over competitors already on the market, says IQWiG, the institute that carries out the preliminary benefit assessment.